Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Vical broadens clinical development of Allovectin-7

Feb. 22, 2001

Therion Biologics and the NCI move CEA-TRICOM cancer vaccine to phase I

Feb. 22, 2001

Phase II trials of SMART 1D10 antibody begin in non-Hodgkin's lymphoma

Feb. 21, 2001

Virulizin granted orphan drug status by FDA

Feb. 20, 2001

Distribution agreement for Pacis BCG terminated by UroCor and BioChem Pharma

Feb. 20, 2001

Melacine now available in Canada for treatment of stage IV melanoma

Feb. 16, 2001

Patient enrollment complete in phase IIb trial of IL-2 gene medicine for H&N cancer

Feb. 16, 2001

First-line therapy with rituximab in follicular lymphoma with low tumor burden

Feb. 13, 2001

Cancer vaccine designed at Progenics induces antitumor immune response in clinical trial

Feb. 13, 2001

ARGENT technology demonstrates potential in prostate cancer

Feb. 12, 2001

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...